News | July 20, 2021
Balaxi Pharmaceuticals Q1 revenue increases by 12%
The company has reported PAT of Rs. 10.7 crore for Q1 FY22, higher by 23% YoY
The company has reported PAT of Rs. 10.7 crore for Q1 FY22, higher by 23% YoY
2-DG was developed by the Institute of Nuclear Medicine & Allied Sciences (INMAS), a laboratory of the Defence Research and Development Organisation (DRDO), in collaboration with Dr. Reddy's
Shilpa's Paracetamol oral thin films are patent protected and are first of this kind in the world
India is expecting to manufacture 30-35 crore COVID-19 vaccines between July - August 2021
The agreements between the parties involve a total fee of Rs. 8 lakh plus taxes for the grant of the licenses on a non-exclusive basis to SPL
The study was conducted in patients with mild to moderate COVID-19
These vaccine doses will be manufactured and stockpiled by the company from August-December 2021
NATCO Pharmaceuticals, Hyderabad; Alembic Pharmaceuticals, Vadodara; Gufic Biosciences Ltd., Gujarat; Emcure Pharmaceuticals, Pune; and Lyka, Gujarat are new manufacturers
We focused on developing the product last year but now our focus is on ramping up our manufacturing capacity
Drop in revenue in the fourth quarter is normal as China is shut down for most of the quarter due to the Chinese New Year holiday
Subscribe To Our Newsletter & Stay Updated
